medigraphic.com

2015, Number 1

<< Back Next >>

Rev Fac Med UNAM 2015; 58 (1)

Unusual location of multiple myeloma lytic lesions with magnetic resonance imaging. Report of two cases

Valencia HO, Valenzuela DJA, Ortiz CK, Romo AC, Zarate OA, Gómez PMG, Hurtado MR

Language: Spanish
References: 12
Page: 40-47
PDF size: 559.43 Kb.


ABSTRACT

Multiple myeloma (MM) is an hematologic malignancy characterized by the proliferation of malignant monoclonal plasma cells in the bone marrow. The diagnostic test for MM is a bone marrow aspirate or biopsy to define the amount of atypical plasma cells and it is the basis of the diagnostic classification system of the International Working Group Myeloma.
MM lesions are lytic bone tissue and are most frequently located in the spine, pelvis, skull and ribs. Bone lesions predominate in these regions of the skeleton and proximal extremities but may occur to a lesser extent on elbows, knees and scapula.
In imaging studies plain radiography remains the primary diagnostic study in detecting destructive bone changes multiple myeloma, however the MRI study is the study of choice because the sensitivity and specificity for the diagnosis of this disease.
Objectives: Report two cases with multiple myeloma infiltration in unusual regions.


REFERENCES

  1. Centers for Disease Control and prevention (CDC) (2014). Bioterrorism agents/diseases. Disponible en: http://www. bt.cdc.gov/agent/agentlist-category.asp

  2. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies a` Kikwit. J Infect Dis. 1999;179 (Suppl 1):S87-S91.

  3. Rodríguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, Bressler D, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179 (Suppl 1):S170-S176.

  4. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013;8:411-40.

  5. Keller MA, Stiehm ER. “Passive immunity in prevention and treatment of infectious diseases”. Clin Microbiol Rev. 2000;13(4):602-14.

  6. Koons C, Chen C, Langreth R for Bloomberg News. Ebola Drug by Tekmira May Be Used on Infected Patients. Aug 8, 2014. Disponible en: http://www.bloomberg.com/ news/2014-08-07/ebola-drug-by-tekmira-may-be-used-oninfected- patients-fda-says.html

  7. Oestereich L, Lü dtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther, S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17-21.

  8. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13:521-31.

  9. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola Virus Disease in Guinea–preliminary report. N Engl J Med. 2014. DOI: 10.1056/NEJMoa1404505.

  10. WHO Ebola Response Team (2014). Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections. N Engl J Med. 2014;371:1481-95. 140416140039002

  11. Legrand J, Grais RF, Boelle PY, Valleron AJ, Flahault A. Understanding the dynamics of Ebola epidemics. Epidemiol Infect. 2007;135:610-21.

  12. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432:904-6.




2020     |     www.medigraphic.com